Receptor (Agonist Time) Cellular Model | Ca2+-Stimulated ACs | Ca2+-Inhibited ACs | βγ-Stimulated1-a ACs | ||||||
---|---|---|---|---|---|---|---|---|---|
AC1 | AC8 | AC3 | AC5 | AC6 | AC2 | AC4 | AC7 | AC9 | |
D2 dopamine (2 h)1-b | Ca2+(+) | PKC (+) | |||||||
HEK293 stable | |||||||||
M2muscarinic (30 min)1-c | FSK (no) | FSK (no) | FSK (no) | ||||||
HEK293 transient | Gαs(no) | Gαs (+) | Gαs(no) | ||||||
μ-Opioid (18 h)1-d | Ca2+ (+) | Ca2+(+) | Ca2+ (no) | FSK (+) | Gαs (+) | PKC (no) | Gαs (−) | Gαs(−) | |
COS-7 transient | FSK (+) | Gαs (no) | Gαs (+) | Gαs(−) | |||||
D2 dopamine (18 h)1-e | Ca2+ (+) | Ca2+(+) | Gαs (−) | Gαs(+) | Gαs (+) | Gαs(−) | Gαs (−) | Gαs(−) | |
COS-7 transient | |||||||||
M4muscarinic (18 h)1-e | Ca2+(+) | Ca2+ (+) | Gαs(−) | Gαs (+) | Gαs(+) | Gαs (−) | Gαs(−) | Gαs (−) | |
COS-7 transient | |||||||||
CB1cannabinoid (18 h)1-f | FSK (+) | FSK (+) | FSK (+) | FSK (+) | FSK (+) | Gαs (−) | Gαs(−) | Gαs (−) | |
COS-7 transient | Gαs(+) | ||||||||
μ-Opioid (18 h)1-g | Ca2+ (+) | FSK (+) | Gαs(−) | ||||||
COS-7 transient | |||||||||
PKC (+) | |||||||||
D2 dopamine (2 h)1-h | Ca2+ (+) | Ca2+(no) | FSK (+) | FSK (no) | Gαs(+) | ||||
HEK293 stable | Gαs(+) | Gαs(no) | |||||||
PKC (+) | |||||||||
D2 dopamine (18 h)1-h | Ca2+(+) | Ca2+ (+) | FSK (+) | FSK (no) | Gαs (+) | ||||
HEK293 stable | FSK (no) | Gαs (+) | Gαs(no) |
(+), increased response; (−), reduced response, (no), no effect; Ca2+, ionomycin/A23187; FSK, forskolin; Gαs, activation of Gαs-coupled receptor; PKC, phorbol, 12-myristate, 13-acetate.
↵1-a Conditionally stimulated by βγ subunits in presence of activated Gαs.
↵1-b Watts and Neve (1996).
↵1-c Thomas and Hoffman (1996).
↵1-d Avidor-Reiss et al. (1997).
↵1-e Nevo et al. (1998).
↵1-f Rhee et al. (2000).
↵1-g Nevo et al. (2000).
↵1-h Cumbay and Watts (2001).